| Name |
CDCA3
|
| Type |
gene
|
| Species |
Homo sapiens
|
| Tissue |
HBEC3, HBEC4 and HBEC5 cells
|
| Experiment Method |
immunohistochemistry;Western blot analyses;qRT-PCR;Immunofluorescence and high content microscopy
|
| Up/Down |
Down
|
| Pro/Anti |
Pro
|
| Funtion Description |
CDCA3 depletion caused a defective G2/M-phase cell cycle progression, upregulation of p21 independent of p53, and induction of cellular senescence.Our findings highlight CDCA3 as a prognostic factor and potential novel therapeutic target in NSCLC through
|
| Regulation Gene |
NA
|
| Year |
2017
|
| Pubmed ID |
28487093
|
| Title |
Expression of CDCA3 Is a Prognostic Biomarker and Potential Therapeutic Target in Non-Small Cell Lung Cancer.
|
| Drug |
NA
|
| Disease |
non-small cell lung cancer
|
| Environment Factors |
NA
|
| Circulating |
NA
|
| Variant |
NA
|
| High-throughput |
NA
|